CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 608 enrolled
Drug / intervention
sitagliptin phosphatedrug
Likely dose
Sitagliptin 100 mg orally once dailyAI-extracted
Key inclusion· 1
  • ✓Currently on metformin monotherapy for at least 10 weeks prior to study entry
Key exclusion· 0

None specified.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00833027
NCT00833027Phase 4Completed
CompareCT.gov

A 24 Week, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Adding Sitagliptin 100 mg Once Daily in Patients With T2DM Who Have Inadequate Glycemic Control on Metformin Therapy

Merck Sharp & Dohme LLC·interventional·Posted Jan 30, 2009·Updated May 15, 2017

In Brief

A Phase 4 clinical trial evaluating sitagliptin phosphate for Diabetes Mellitus. Completed, enrolled 608 participants.

Detailed Summary

Canadian physicians to experience in real life clinical practice the efficacy and tolerability of adding sitagliptin to their patients who have their glycemic levels inadequately controlled while on metformin

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus
Countries--
Collaborators--

Timeline

Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 30, 2009
Enrollment StartMar 1, 2008
Primary CompletionOct 30, 2009
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 17.4 years ago

Interventions

sitagliptin phosphatedrug

Sitagliptin 100 mg/day - tablet for 24 weeks